Stockscreener 앱 받기
7.70
1.85%
0.14
시장 영업 전:
7.67
-0.03
-0.39%
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
PARP Inhibitor Biomarkers Market Top PlayersMyriad Genetics, - openPR.com
Myriad Genetics Quarterly Earnings Preview: What to ExpectNews and Statistics - IndexBox
What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings - Yahoo Finance
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help - Hometown Stations
Press Release Distribution & PR Platform - ACCESS Newswire
Molecular Diagnostics Market to Witness Remarkable Growth with - openPR.com
Myriad Genetics: Significantly Undervalued With Profitability In Sight - Seeking Alpha
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight - GlobeNewswire Inc.
Myriad Genetics (MYGN) Survey Highlights Views on Mental Health Medication | MYGN Stock News - GuruFocus
Concerns about Mental Health Medication Side Effects Remain - GlobeNewswire
Mental Health Breakthrough: New Genetic Test Could End Medication Trial-and-Error, Study Shows - Stock Titan
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 - GlobeNewswire
Myriad Genetics Announces Triple Investor Event: Q1 Earnings Plus Two Elite Healthcare Conferences - Stock Titan
10-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad Genetics Highlights MRD Clinical Validity Data at America - GuruFocus
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting - The Manila Times
Breakthrough Cancer Detection Test Achieves 94% Survival Rate, Doubles Treatment Window in Kidney Cancer Study - Stock Titan
3 Healthcare Stocks That Concern Us - Yahoo Finance
Myriad Genetics Unveils Promising Clinical Data on Precise MRD Test for Oligometastatic Clear-Cell Renal Cell Carcinoma at AACR Annual Meeting - Nasdaq
Myriad Genetics stock hits 52-week low at $7.28 amid sharp decline - Investing.com India
Myriad Genetics stock hits 52-week low at $7.28 amid sharp decline By Investing.com - Investing.com South Africa
Microtomes Market Projected To Witness Substantial Growth, - openPR.com
Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with - GuruFocus
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? - Yahoo Finance
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing | MYGN Stock News - GuruFocus
Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with GeneSight Test | MYGN Stock News - GuruFocus
Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients - Nasdaq
Myriad Genetics Announces Study Results Show Patients with - GlobeNewswire
New Study: Depression Patients See 40% Drop in Drug Complications with GeneSight Genetic Test - Stock Titan
Demystifying Myriad Genetics: Insights From 10 Analyst Reviews - Benzinga
Pancreatic Cancer Market Growth, Trends & Forecast 2024-2031 | - openPR.com
Myriad Genetics price target lowered to $9 from $11 at BofA - Yahoo Finance
Myriad Genetics (MYGN) Sees Price Target Lowered by BofA Amid Po - GuruFocus
8-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Genetic Screening Testing for Preventive Health Market Top - openPR.com
Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN
Guggenheim Downgrades Myriad Genetics to Neutral From Buy - marketscreener.com
Myriad Genetics Announces Inducement Awards - The Manila Times
Myriad Genetics Announces Inducement Awards | MYGN Stock News - GuruFocus
0.34%
0.46%
자본화:
|
볼륨(24시간):